Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En 24-ugers undersøgelse af effektiviteten og sikkerheden af ​​BLU-5937 hos voksne med refraktær kronisk hoste (CALM-2) (CALM-2)

17. november 2026 opdateret af: Bellus Health Inc. - a GSK company

Et fase 3, 24-ugers, randomiseret, dobbeltblindt, placebokontrolleret, parallelarms effektivitet og sikkerhedsundersøgelse med Open-Label forlængelse af BLU-5937 hos voksne deltagere med refraktær kronisk hoste, inklusive uforklarlig kronisk hoste

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1019

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Coffs Harbour, New South Wales, Australien, 2450
        • GSK Investigational Site
      • Macquarie University, New South Wales, Australien, 2109
        • GSK Investigational Site
      • New Lambton, New South Wales, Australien, 2305
        • GSK Investigational Site
      • St Leonards, New South Wales, Australien, 2065
        • GSK Investigational Site
    • Queensland
      • Chermside, Queensland, Australien, 4032
        • GSK Investigational Site
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • GSK Investigational Site
    • Victoria
      • St Albans, Victoria, Australien, 3021
        • GSK Investigational Site
    • Western Australia
      • Nedlands, Western Australia, Australien, 6009
        • GSK Investigational Site
      • Spearwood, Western Australia, Australien, 6163
        • GSK Investigational Site
      • Burlington, Canada, ON L7N 3V2
        • GSK Investigational Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • GSK Investigational Site
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • GSK Investigational Site
      • Hamilton, Ontario, Canada, L8N 3Z5
        • GSK Investigational Site
      • Hamilton, Ontario, Canada, L8L 5G4
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5T 3A9
        • GSK Investigational Site
      • Windsor, Ontario, Canada, N8X 1T3
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H1Y3H5
        • GSK Investigational Site
      • Québec, Quebec, Canada, G1V 4W2
        • GSK Investigational Site
      • Québec, Quebec, Canada, G1V 4T3
        • GSK Investigational Site
      • Saint-Charles-Borromée, Quebec, Canada, J6E 2B4
        • GSK Investigational Site
      • Trois-Rivières, Quebec, Canada, G8T 7A1
        • GSK Investigational Site
      • Victoriaville, Quebec, Canada, G6P 3Z8
        • GSK Investigational Site
      • Belfast, Det Forenede Kongerige, BT7 2EB
        • GSK Investigational Site
      • Bristol, Det Forenede Kongerige, BS374AX
        • GSK Investigational Site
      • Chelmsford, Det Forenede Kongerige, CM1 7ET
        • GSK Investigational Site
      • Corby, Det Forenede Kongerige, NN17 2UR
        • GSK Investigational Site
      • Corby, Det Forenede Kongerige, NN18 9EZ
        • GSK Investigational Site
      • Coventry, Det Forenede Kongerige, CV3 4FJ
        • GSK Investigational Site
      • Hayle, Det Forenede Kongerige, TR27 5DT
        • GSK Investigational Site
      • Hull, Det Forenede Kongerige, HU16 5JQ
        • GSK Investigational Site
      • London, Det Forenede Kongerige, SE5 9RS
        • GSK Investigational Site
      • Orpington, Det Forenede Kongerige, BR5 3QG
        • GSK Investigational Site
      • Peterborough, Det Forenede Kongerige, PE3 9GZ
        • GSK Investigational Site
      • Preston, Det Forenede Kongerige, PR2 9HT
        • GSK Investigational Site
      • Shipley, Det Forenede Kongerige, BD18 3SA
        • GSK Investigational Site
      • Tyne and Wear, Det Forenede Kongerige, NE29 8NH
        • GSK Investigational Site
      • Wishaw, Det Forenede Kongerige, ML2 0DP
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, Det Forenede Kongerige, HA6 2RN
        • GSK Investigational Site
    • West Yorkshire
      • Bradford, West Yorkshire, Det Forenede Kongerige, BD9 6RJ
        • GSK Investigational Site
    • Alabama
      • Foley, Alabama, Forenede Stater, 36535
        • GSK Investigational Site
    • Arizona
      • Litchfield Park, Arizona, Forenede Stater, 85340
        • GSK Investigational Site
      • Phoenix, Arizona, Forenede Stater, 85032
        • GSK Investigational Site
    • California
      • Los Angeles, California, Forenede Stater, 90025
        • GSK Investigational Site
      • Los Angeles, California, Forenede Stater, 90048
        • GSK Investigational Site
      • Paramount, California, Forenede Stater, 90723-5433
        • GSK Investigational Site
      • Sacramento, California, Forenede Stater, 95661
        • GSK Investigational Site
      • San Diego, California, Forenede Stater, 92120
        • GSK Investigational Site
      • San Diego, California, Forenede Stater, 92108
        • GSK Investigational Site
      • San Jose, California, Forenede Stater, 95117
        • GSK Investigational Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012
        • GSK Investigational Site
      • Colorado Springs, Colorado, Forenede Stater, 80923
        • GSK Investigational Site
      • Denver, Colorado, Forenede Stater, 80230-6406
        • GSK Investigational Site
      • Wheat Ridge, Colorado, Forenede Stater, 96001
        • GSK Investigational Site
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • GSK Investigational Site
    • Florida
      • Daytona Beach, Florida, Forenede Stater, 32117
        • GSK Investigational Site
      • DeBary, Florida, Forenede Stater, 32713-2260
        • GSK Investigational Site
      • Fort Lauderdale, Florida, Forenede Stater, 33324
        • GSK Investigational Site
      • Jacksonville, Florida, Forenede Stater, 32224
        • GSK Investigational Site
      • Leesburg, Florida, Forenede Stater, 34748
        • GSK Investigational Site
      • Santa Rosa Beach, Florida, Forenede Stater, 32459
        • GSK Investigational Site
      • Sarasota, Florida, Forenede Stater, 34239
        • GSK Investigational Site
      • Sweetwater, Florida, Forenede Stater, 33172-2732
        • GSK Investigational Site
    • Georgia
      • Cumming, Georgia, Forenede Stater, 30041-7536
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • GSK Investigational Site
      • River Forest, Illinois, Forenede Stater, 60305
        • GSK Investigational Site
    • Iowa
      • West Des Moines, Iowa, Forenede Stater, 50266-8216
        • GSK Investigational Site
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40509-1801
        • GSK Investigational Site
    • Maryland
      • Chevy Chase, Maryland, Forenede Stater, 20815
        • GSK Investigational Site
    • Massachusetts
      • Methuen, Massachusetts, Forenede Stater, 01844
        • GSK Investigational Site
      • North Dartmouth, Massachusetts, Forenede Stater, 02747
        • GSK Investigational Site
    • Michigan
      • Ypsilanti, Michigan, Forenede Stater, 48197
        • GSK Investigational Site
    • Minnesota
      • Edina, Minnesota, Forenede Stater, 55435
        • GSK Investigational Site
      • Rochester, Minnesota, Forenede Stater, 55905-0001
        • GSK Investigational Site
      • Woodbury, Minnesota, Forenede Stater, 55125
        • GSK Investigational Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63141
        • GSK Investigational Site
      • St Louis, Missouri, Forenede Stater, 63141-6282
        • GSK Investigational Site
    • Montana
      • Missoula, Montana, Forenede Stater, 59808
        • GSK Investigational Site
    • Nebraska
      • Lincoln, Nebraska, Forenede Stater, 68516
        • GSK Investigational Site
      • Omaha, Nebraska, Forenede Stater, 68124
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28211
        • GSK Investigational Site
      • Gastonia, North Carolina, Forenede Stater, 28054-7481
        • GSK Investigational Site
      • Winston-Salem, North Carolina, Forenede Stater, 27103-3921
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43235
        • GSK Investigational Site
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74136
        • GSK Investigational Site
    • Oregon
      • Portland, Oregon, Forenede Stater, 97213
        • GSK Investigational Site
    • Pennsylvania
      • Danville, Pennsylvania, Forenede Stater, 17822-9800
        • GSK Investigational Site
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • GSK Investigational Site
    • Rhode Island
      • Warwick, Rhode Island, Forenede Stater, 02886
        • GSK Investigational Site
    • South Carolina
      • Anderson, South Carolina, Forenede Stater, 29621
        • GSK Investigational Site
      • Charleston, South Carolina, Forenede Stater, 29412
        • GSK Investigational Site
      • Charleston, South Carolina, Forenede Stater, 29406
        • GSK Investigational Site
      • Gaffney, South Carolina, Forenede Stater, 29340-4737
        • GSK Investigational Site
    • Tennessee
      • Franklin, Tennessee, Forenede Stater, 37067
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75231-4307
        • GSK Investigational Site
      • Round Rock, Texas, Forenede Stater, 78681
        • GSK Investigational Site
      • San Antonio, Texas, Forenede Stater, 78258
        • GSK Investigational Site
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23507
        • GSK Investigational Site
    • Washington
      • Bellingham, Washington, Forenede Stater, 98225
        • GSK Investigational Site
      • Faridabad, Indien, 121006
        • GSK Investigational Site
      • Nagpur, Indien, 44009
        • GSK Investigational Site
      • Nashik, Indien, 422001
        • GSK Investigational Site
      • Visakhapatnam, Indien, 530017
        • GSK Investigational Site
      • Aichi, Japan, 467-8602
        • GSK Investigational Site
      • Akita, Japan, 010-8543
        • GSK Investigational Site
      • Chiba, Japan, 260-8677
        • GSK Investigational Site
      • Fukui, Japan, 910-1193
        • GSK Investigational Site
      • Fukuoka, Japan, 812-8582
        • GSK Investigational Site
      • Fukuoka, Japan, 819-8555
        • GSK Investigational Site
      • Fukuoka, Japan, 807-8556
        • GSK Investigational Site
      • Fukushima, Japan, 960-1295
        • GSK Investigational Site
      • Gifu, Japan, 509-6134
        • GSK Investigational Site
      • Gifu, Japan, 501-6062
        • GSK Investigational Site
      • Gifu, Japan, 153-8515
        • GSK Investigational Site
      • Hiroshima, Japan, 735-8585
        • GSK Investigational Site
      • Hokkaido, Japan, 064-0804
        • GSK Investigational Site
      • Hyōgo, Japan, 670-8520
        • GSK Investigational Site
      • Hyōgo, Japan, 663-8501
        • GSK Investigational Site
      • Hyōgo, Japan, 672-8064
        • GSK Investigational Site
      • Hyōgo, Japan, 674-0063
        • GSK Investigational Site
      • Ibaraki, Japan, 319-1113
        • GSK Investigational Site
      • Kagawa, Japan, 761-8073
        • GSK Investigational Site
      • Kagoshima, Japan, 890-8520
        • GSK Investigational Site
      • Kanagawa, Japan, 232-0024
        • GSK Investigational Site
      • Kanagawa, Japan, 234-8503
        • GSK Investigational Site
      • Kanagawa, Japan, 231-8682
        • GSK Investigational Site
      • Kyoto, Japan, 606-8507
        • GSK Investigational Site
      • Kyoto, Japan, 612-8555
        • GSK Investigational Site
      • Mie, Japan, 515-8544
        • GSK Investigational Site
      • Miyazaki, Japan, 889-4304
        • GSK Investigational Site
      • Nagasaki, Japan, 852-8501
        • GSK Investigational Site
      • Nankoku-shi, Japan, 783-8509
        • GSK Investigational Site
      • Niigata, Japan, 950-1197
        • GSK Investigational Site
      • Osaka, Japan, 545-8586
        • GSK Investigational Site
      • Osaka, Japan, 589-8511
        • GSK Investigational Site
      • Osaka, Japan, 591-8555
        • GSK Investigational Site
      • Osaka, Japan, 577-0843
        • GSK Investigational Site
      • Saitama, Japan, 350-0495
        • GSK Investigational Site
      • Shizuoka, Japan, 420-8527
        • GSK Investigational Site
      • Shizuoka, Japan, 432-8002
        • GSK Investigational Site
      • Shizuoka, Japan, 426-8677
        • GSK Investigational Site
      • Shizuoka, Japan, 433-8558
        • GSK Investigational Site
      • Tochigi, Japan, 321-0293
        • GSK Investigational Site
      • Tokyo, Japan, 150-8935
        • GSK Investigational Site
      • Tokyo, Japan, 104-0031
        • GSK Investigational Site
      • Tokyo, Japan, 173-8606
        • GSK Investigational Site
      • Tokyo, Japan, 204-8522
        • GSK Investigational Site
      • Tokyo, Japan, 140-8522
        • GSK Investigational Site
      • Yokohama, Japan, 236-0004
        • GSK Investigational Site
      • Changsha, Kina, 410008
        • GSK Investigational Site
      • Chengdu, Kina, 610041
        • GSK Investigational Site
      • Chongqing, Kina, 408099
        • GSK Investigational Site
      • Dongguan, Kina, 523326
        • GSK Investigational Site
      • Ganzhou, Kina, 341000
        • GSK Investigational Site
      • Guangzhou, Kina, 510000
        • GSK Investigational Site
      • Hangzhou, Kina, 310003
        • GSK Investigational Site
      • Hefei, Kina, 230001
        • GSK Investigational Site
      • Hefei, Kina, 230022
        • GSK Investigational Site
      • Hohhot, Kina, 010017
        • GSK Investigational Site
      • Huizhou, Kina, 516001
        • GSK Investigational Site
      • Huizhou, Kina, 516000
        • GSK Investigational Site
      • Jiangsu, Kina, 221004
        • GSK Investigational Site
      • Jinan, Kina, 250021
        • GSK Investigational Site
      • Jingzhou, Kina, 434020
        • GSK Investigational Site
      • Kunming, Kina, 650032
        • GSK Investigational Site
      • Liuzhou, Kina
        • GSK Investigational Site
      • Meizhou, Kina, 514700
        • GSK Investigational Site
      • Nanchang, Kina, 330038
        • GSK Investigational Site
      • Pingxiang, Kina, 337055
        • GSK Investigational Site
      • Shanghai, Kina, 200032
        • GSK Investigational Site
      • Shanghai, Kina, 200065
        • GSK Investigational Site
      • Shanghai, Kina, 200080
        • GSK Investigational Site
      • Shenyang, Kina, 110004
        • GSK Investigational Site
      • Shenzhen, Kina, 518053
        • GSK Investigational Site
      • Taizhou, Kina, 317000
        • GSK Investigational Site
      • Wenzhou, Kina, 325000
        • GSK Investigational Site
      • Xiamen, Kina, 361004
        • GSK Investigational Site
      • Yangzhou, Kina, 225001
        • GSK Investigational Site
      • Yinchuan, Kina
        • GSK Investigational Site
      • Zhanjiang, Kina, 524045
        • GSK Investigational Site
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 830001
        • GSK Investigational Site
      • Auckland, New Zealand, 0626
        • GSK Investigational Site
      • Christchurch, New Zealand, 8011
        • GSK Investigational Site
      • Christchurch, New Zealand, 8013
        • GSK Investigational Site
      • Dunedin, New Zealand, 9016
        • GSK Investigational Site
      • Hamilton, New Zealand, 3200
        • GSK Investigational Site
      • Kapiti, New Zealand, 5036
        • GSK Investigational Site
      • Nelson, New Zealand, 7011
        • GSK Investigational Site
      • New Lynn, New Zealand, 0600
        • GSK Investigational Site
      • Rotorua, New Zealand, 3010
        • GSK Investigational Site
      • Tauranga, New Zealand, 3110
        • GSK Investigational Site
    • Hawke's Bay Region
      • Havelock North, Hawke's Bay Region, New Zealand, 3410
        • GSK Investigational Site
    • Upper Hutt
      • Ebdentown, Upper Hutt, New Zealand, 5018
        • GSK Investigational Site
      • Bardejov, Slovakiet, 08501
        • GSK Investigational Site
      • Bardejov, Slovakiet, 8501
        • GSK Investigational Site
      • Humenné, Slovakiet, 06601
        • GSK Investigational Site
      • Kežmarok, Slovakiet, 060 01
        • GSK Investigational Site
      • Košice, Slovakiet, 040 01
        • GSK Investigational Site
      • Prievidza, Slovakiet, 97101
        • GSK Investigational Site
      • Spišská Nová Ves, Slovakiet, 052 01
        • GSK Investigational Site
      • Incheon, Sydkorea, 21431
        • GSK Investigational Site
      • Jeonju, Sydkorea, 54907
        • GSK Investigational Site
      • Pusan, Sydkorea, 49241
        • GSK Investigational Site
      • Seongnam, Sydkorea, 13620
        • GSK Investigational Site
      • Seoul, Sydkorea, 03080
        • GSK Investigational Site
      • Seoul, Sydkorea, 06591
        • GSK Investigational Site
      • Seoul, Sydkorea, 03312
        • GSK Investigational Site
      • Seoul, Sydkorea, 08308
        • GSK Investigational Site
      • Seoul, Sydkorea, 03722
        • GSK Investigational Site
      • Seoul, Sydkorea, 5030
        • GSK Investigational Site
      • Seoul, Sydkorea, 5505
        • GSK Investigational Site
      • Seoul, Sydkorea, 6351
        • GSK Investigational Site
      • Wŏnju, Sydkorea, 26426
        • GSK Investigational Site
      • Changhua, Taiwan, 50006
        • GSK Investigational Site
      • Kaohsiung City, Taiwan, 807
        • GSK Investigational Site
      • Kaohsiung City, Taiwan, 82445
        • GSK Investigational Site
      • Taoyuan, Taiwan, 333
        • GSK Investigational Site
      • Brandýs nad Labem, Tjekkiet, 25001
        • GSK Investigational Site
      • Brno, Tjekkiet, 62500
        • GSK Investigational Site
      • Kralupy nad Vltavou, Tjekkiet, 278 01
        • GSK Investigational Site
      • Miroslav, Tjekkiet, 671 72
        • GSK Investigational Site
      • Olomouc, Tjekkiet, 77900
        • GSK Investigational Site
      • Prague, Tjekkiet, 14800
        • GSK Investigational Site
      • Strakonice, Tjekkiet, 38601
        • GSK Investigational Site
      • Berlin, Tyskland, 10117
        • GSK Investigational Site
      • Berlin, Tyskland, 10969
        • GSK Investigational Site
      • Bochum, Tyskland, 44787
        • GSK Investigational Site
      • Dresden, Tyskland, 01069
        • GSK Investigational Site
      • Essen, Tyskland, 45355
        • GSK Investigational Site
      • Frankfurt, Tyskland, 60596
        • GSK Investigational Site
      • Frankfurt am Main, Tyskland, 60315
        • GSK Investigational Site
      • Hamburg, Tyskland, 20253
        • GSK Investigational Site
      • Lübeck, Tyskland, 23552
        • GSK Investigational Site
      • Marburg, Tyskland, 35037
        • GSK Investigational Site
      • München, Tyskland, 81241
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Tyskland, 69126
        • GSK Investigational Site
      • Karlsruhe, Baden-Wurttemberg, Tyskland, 76137
        • GSK Investigational Site
    • Hesse
      • Darmstadt, Hesse, Tyskland, 64283
        • GSK Investigational Site
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • GSK Investigational Site
      • Frankfurt am Main, Hesse, Tyskland, 60596
        • GSK Investigational Site
      • Neu-Isenburg, Hesse, Tyskland, 63263
        • GSK Investigational Site
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland, 30159
        • GSK Investigational Site
      • Hanover, Lower Saxony, Tyskland, 30173
        • GSK Investigational Site
      • Peine, Lower Saxony, Tyskland, 31224
        • GSK Investigational Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Tyskland, 06108
        • GSK Investigational Site
    • Schleswig-Holstein
      • Geesthacht, Schleswig-Holstein, Tyskland, 21502
        • GSK Investigational Site
      • Schleswig, Schleswig-Holstein, Tyskland, 24837
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Capable of giving signed informed consent
  • Refractory chronic cough (including unexplained chronic cough) for at least one year
  • Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

Exclusion Criteria:

  • Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
  • Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
  • Respiratory tract infection within 4 weeks before screening
  • Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
  • History of malignancy in the last 5 years
  • History of alcohol or drug abuse within the last 3 years
  • Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
  • Previous participation in a BLU-5937 trial

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: BLU-5937 25 mg

BLU-5937 oral dose 25 mg twice a day.

Oral administration of BLU-5937 Tablets

Andre navne:
  • Camlipixant
Eksperimentel: BLU-5937 50 mg

BLU-5937 oral dose 50 mg twice a day.

Oral administration of BLU-5937 Tablets

Andre navne:
  • Camlipixant
Placebo komparator: Placebo

Matching Placebo for BLU-5937 oral dose twice a day.

Oral administration of matching placebo for BLU-5937 Tablets

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline i vitale tegn: systolisk og diastolisk blodtryk (millimeter kviksølv [mm Hg]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Skift fra baseline i vital tegn: puls (beats pr. Minut) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Skift fra baseline i vital tegn: åndedrætsfrekvens (åndedræt pr. Minut) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Skift fra baseline i vital tegn: kropstemperatur (grader celsius) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Skift fra baseline i vital tegn: Vægt (kg [kg]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i mandlig reproduktiv hormon: total testosteron (nanomoler pr. Liter [nmol/l]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i mandlige reproduktive hormoner: follikelstimulerende hormon [FSH] og luteiniserende hormon [LH] (internationale enheder pr. Liter [IU/L]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i mandlig reproduktiv hormon: inhibin B (nanogrammer pr. Liter [ng/l]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologi Parameter: Røde blodlegemer (RBC) tælling (10^12 celler pr. Liter) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologiparametre: hæmoglobin og gennemsnitlig corpuskulær hæmoglobinkoncentration (MCHC) (gram pr. Liter [g/l]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologi Parameter: Hematocrit (procentdel) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologi Parameter: Gennemsnitlig corpuskulær volumen (MCV) (femtoliters [FL]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologiparameter: gennemsnitlig corpuskulær hæmoglobin (MCH) (picograms pr. Celle [PG/celle]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologi Parameter: Red Cell Distribution Bredde (RDW) (procentdel) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i hæmatologiparametre: hvide blodlegemer (WBC) tælling (neutrofiler, lymfocytter, monocytter, eosinofiler og basofiler) og blodpladetælling (10^9 celler pr. Liter) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi-parametre: alaninaminotransferase (ALT), aspartataminotransferase (AST) og gamma-glutamyltransferase (GGT) (enheder pr. Liter [U/L]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi -parametre: alkalisk phosphatase (ALP) og kreatinkinase (CK) (internationale enheder pr. Liter [IU/L]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi -parametre: total bilirubin, direkte og indirekte bilirubin og kreatinin (mikromol pr. Liter) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi -parametre: natrium, kalium, chlorid, calcium, magnesium, bicarbonat, glukose og blodurinstofnitrogen (BUN) (millimoler pr. Liter [mmol/L]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi -parametre: protein og albumin (gram pr. Liter [g/l]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i klinisk kemi Parameter: estimeret glomerulær filtreringshastighed (EGFR) (ml pr. Minut pr. 1,73 meter kvadrat [ml/min/1,73 m^2]) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i kliniske kemi -parametre: Prothrombin Time (PT) og aktiveret delvis thromboplastin -tid (APTT) (sekunder) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i elektrokardiogram (EKG) værdi: hjerterytme (beats pr. Minut) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
Ændring fra baseline i EKG -værdi: PR -interval, QT -interval, RR -interval, QRS -interval og korrigeret QT -interval ved hjælp af Fridericias formel (QTCF) (millisekunder) i uge 24
Tidsramme: Baseline, uge ​​24
Baseline, uge ​​24
24-Hour Cough Frequency
Tidsramme: Week 24

Assessed using an ambulatory cough monitor

Week 24
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24
Tidsramme: Up to Week 24

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

Up to Week 24
Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24
Tidsramme: Up to Week 24

An AEMI is an event of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring is appropriate. The following are AEMIs for this study: taste disturbance, oral hypoesthesia, oral paresthesia, and new or worsening findings of the cornea.

Up to Week 24
Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24
Tidsramme: Up to Week 24

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

Up to Week 24
Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24
Tidsramme: Up to Week 24

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with that product. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death, is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per the medical or scientific judgment of the Investigator.

Up to Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Cough Severity Visual Analogue Scale at Week 24
Tidsramme: Baseline, Week 24

Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

Baseline, Week 24
Percentage of Participants With Greater than or Equal to (>=) 30 mm Reduction From Baseline in Cough Severity Visual Analog Scale at Week 24
Tidsramme: Baseline, Week 24

Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analogue scale where higher scores indicate greater severity.

Baseline, Week 24
Awake Cough Frequency at Week 24
Tidsramme: Week 24

Assessed using an ambulatory cough monitor

Week 24
Percentage of Participants With >= 30 percent (%) Reduction From Baseline in 24-Hour Cough Frequency at Week 24
Tidsramme: Baseline, Week 24

Assessed using an ambulatory cough monitor

Baseline, Week 24
Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Tidsramme: Baseline, Week 24

The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

Baseline, Week 24
Percentage of Participants With a >= 1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Tidsramme: Baseline, Week 24

The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the patient responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the impact of cough on 3 domains: physical, psychological, and social. Domain scores range from 1-7, and the total score ranges from 3 - 21; a higher score indicates a better quality of life.

Baseline, Week 24
Change from Baseline in the Chronic Cough Diary (CCD) Score at Week 24
Tidsramme: Baseline, Week 24

The CCD is a participant-completed daily diary used to assess chronic cough. The CCD score ranges from 0 to 16, with a higher score indicating worse symptoms.

Baseline, Week 24
Percentage of Participants with CCD Response at Week 24
Tidsramme: Week 24

Percentage of participants with CCD response will be summarized.

Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. december 2022

Primær færdiggørelse (Faktiske)

10. juni 2026

Studieafslutning (Faktiske)

2. september 2026

Datoer for studieregistrering

Først indsendt

18. oktober 2022

Først indsendt, der opfyldte QC-kriterier

25. oktober 2022

Først opslået (Faktiske)

31. oktober 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 221851
  • BUS-P3-02 (Anden identifikator: Bellus Health Inc)
  • 2024-513462-19-00 (Anden identifikator: EU CT Number)
  • BUS-P3-02 (Anden identifikator: Company)
  • 2022-000188-38 (Registry Identifier: EudraCT (EU))
  • 2024-513462-19-00 (Registry Identifier: CTIS (EU))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner